申请人:BANYU PHARMACEUTICAL CO., LTD.
公开号:EP0930298A1
公开(公告)日:1999-07-21
This invention relates to novel fluorine-containing 1,4-disubstituted piperidine derivatives represented by a general formula [I]
and pharmaceutically acceptable salts thereof,
[wherein:
Ar represents an aryl group or a hetero-aryl group having 1 to 2 hetero atoms selected from a group consisting of nitrogen, oxygen and sulfur (any 1 to 3 hydrogen atoms on the ring of said aryl or heteroaryl group may be substituted with lower alkyl, etc.);
R1 represents C3-C6 cycloalkyl whose any 1-4 hydrogen atmos may be substituted with fluorine atoms(s);
R2 represents C5-C15 saturated or unsaturated aliphatic hydrocarbon groups whose any 1 to 6 hydrogen atoms may be substituted with fluorine atom(s), aralkyl, arylalkenyl, heteroarylalkyl or heteroarylalkenyl group having 1 to 2 hetero atoms selected from a group consisting of nitrogen, oxygen and sulfur (optionally any 1 to 3 hydrogen atoms on the ring in said aralkyl, arylalkenyl, hetero-arylalkyl or heteroarylalkenyl group may be substituted with lower alkyl, trifluoromethyl, cyano, hydroxyl, nitro, lower alkoxycarbonyl, halogen, lower alkoxy or amino, etc. ; and
X stands for O or NH,
provided that at least either one of R1 and R2 contains one or more fluorine atoms].
The compounds of the present invention have selective antagonistic activity for muscarinic M3 receptors, and exhibit excellent oral activity, duration of action and pharmacokinetics, so that they have little side effects and are safe and effective. Therefore they are useful for treatment or prophylaxis of respiratory diseases, urinary diseases and digestive diseases.
本发明涉及通式[I]代表的新型含氟 1,4-二取代哌啶衍生物
及其药学上可接受的盐类、
其中
Ar 代表芳基或杂芳基,其 1 至 2 个杂原子选自氮、氧和硫组成的组 (所述芳基或杂芳基环上的任何 1 至 3 个氢原子可被低级烷基等取代);
R1 代表 C3-C6 环烷基,其任意 1-4 个氢原子可被氟原子取代;
R2 代表 C5-C15 饱和或不饱和脂肪族烃基,其任意 1-6 个氢原子可被氟原子取代;R3 代表芳烷基、芳烯基、杂芳烷基或杂芳基烯基,其 1-2 个杂原子选自由氮、氧和硫组成的组、氧和硫(上述芳烷基、芳烯基、杂芳烷基或杂芳基烯基的环上任意 1 至 3 个氢原子可任选被低级烷基、三氟甲基、氰基、羟基、硝基、低级烷氧基羰基、卤素、低级烷氧基或氨基等取代);以及和
X 代表 O 或 NH、
条件是 R1 和 R2 中至少有一个含有一个或多个氟原子]。
本发明的化合物对毒蕈碱类 M3 受体具有选择性拮抗活性,并表现出良好的口服活性、作用持续时间和药代动力学,因此副作用小且安全有效。因此,它们可用于治疗或预防呼吸系统疾病、泌尿系统疾病和消化系统疾病。